drugset / Trial / NCT07226232

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

NCT07226232

Phase 3 Not yet recruiting 240 enrolled VA Office of Research and Development
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.

Timeline

Start
2026-07-30
Primary completion
2030-12-02
Completion
2031-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 25 mg